Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Aug 31, 2024 | (FY)May 31, 2024 | (Q4)May 31, 2024 | (Q3)Feb 29, 2024 | (Q2)Nov 30, 2023 | (Q1)Aug 31, 2023 | (FY)May 31, 2023 | (Q4)May 31, 2023 | (Q3)Feb 28, 2023 | (Q2)Nov 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 4.71%5.84B | 5.34%22.24B | 5.17%5.58B | 3.56%5.51B | 5.88%5.57B | 6.79%5.58B | 7.45%21.11B | 7.56%5.31B | 9.94%5.32B | 7.61%5.26B |
Cost of revenue | 1.68%3.09B | 5.61%12.83B | -0.94%3.29B | 9.91%3.27B | 9.58%3.23B | 4.69%3.04B | 5.91%12.15B | 9.54%3.33B | 2.53%2.97B | 7.25%2.94B |
Gross profit | 8.36%2.75B | 4.98%9.41B | 15.41%2.29B | -4.48%2.24B | 1.17%2.34B | 9.43%2.54B | 9.60%8.96B | 4.41%1.98B | 21.03%2.34B | 8.07%2.32B |
Operating expense | 8.11%2.29B | 7.57%6.14B | 5.53%1.31B | 9.88%1.22B | -1.41%1.5B | 14.92%2.12B | 8.21%5.71B | 11.02%1.24B | 14.26%1.11B | -0.17%1.52B |
Operating profit | 9.64%455.3M | 0.44%3.27B | 31.81%983.01M | -17.30%1.02B | 6.05%847.77M | -12.05%415.26M | 12.12%3.26B | -5.00%745.75M | 27.79%1.24B | 28.14%799.38M |
Net non-operating interest income (expenses) | 37.74%792K | 138.77%2.49M | 267.87%813K | 104.14%641K | 175.30%457K | 69.12%575K | 49.50%1.04M | -10.89%221K | 55.45%314K | 52.29%166K |
Non-operating interest income | 37.74%792K | 138.77%2.49M | 267.87%813K | 104.14%641K | 175.30%457K | 69.12%575K | 49.50%1.04M | -10.89%221K | 55.45%314K | 52.29%166K |
Net investment income | -323.32%-63.55M | 0.70%65.1M | 234.00%21.36M | -18.25%23.38M | 57.18%-8.09M | -41.39%28.46M | -4.76%64.65M | -91.47%6.39M | 47.86%28.6M | -32.75%-18.89M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -224.93%-25.12M | -92.26%-20.87M | -4.25M | 0 | 90.58%-7.73M | -10.85M | 0 | |||
Less:Other special charges | ---- | 224.93%25.12M | 92.26%20.87M | --4.25M | ---- | ---- | 135.81%7.73M | --10.85M | ---- | ---- |
Other non-operating income (expenses) | -435.29%-4.29M | 194.70%24.2M | 164.47%19.53M | 1,065.26%5.03M | -87.59%439K | -132.71%-802K | -128.10%-25.55M | -134.95%-30.3M | -86.07%-521K | 158.93%3.54M |
Income before tax | -12.46%388.24M | 1.48%3.34B | 41.14%1B | -17.20%1.05B | 7.19%840.58M | -15.67%443.49M | 12.17%3.29B | -24.89%711.21M | 35.00%1.27B | 47.33%784.19M |
Income tax | 616.41%108.35M | 1.15%900.76M | 170.82%316.74M | -17.48%318.01M | 8.46%250.89M | -90.36%15.12M | 14.96%890.54M | -56.24%116.96M | 100.09%385.38M | 48.24%231.31M |
Net income | -34.66%279.89M | 1.60%2.44B | 15.62%687.1M | -17.08%731.31M | 6.66%589.69M | 16.09%428.37M | 11.17%2.4B | -12.56%594.26M | 18.20%881.92M | 46.95%552.88M |
Net income continuous operations | -34.66%279.89M | 1.60%2.44B | 15.62%687.1M | -17.08%731.31M | 6.66%589.69M | 16.09%428.37M | 11.17%2.4B | -12.56%594.26M | 18.20%881.92M | 46.95%552.88M |
Noncontrolling interests | 324K | -1.36M | 0 | |||||||
Net income attributable to the company | -34.74%279.57M | 1.66%2.44B | 15.85%688.46M | -17.08%731.31M | 6.66%589.69M | 16.09%428.37M | 11.17%2.4B | -12.56%594.26M | 18.20%881.92M | 46.95%552.88M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -34.74%279.57M | 1.66%2.44B | 15.85%688.46M | -17.08%731.31M | 6.66%589.69M | 16.09%428.37M | 11.17%2.4B | -12.56%594.26M | 18.20%881.92M | 46.95%552.88M |
Gross dividend payment | ||||||||||
Basic earnings per share | -34.85%12.655 | 1.46%110.425 | 15.66%31.17 | -17.25%33.1 | 6.46%26.715 | 15.87%19.425 | 10.91%108.835 | -12.77%26.95 | 17.96%40 | 46.63%25.095 |
Diluted earnings per share | -34.86%12.62 | 1.46%110.14 | 15.66%31.09 | -17.25%33.1 | 6.46%26.715 | 15.84%19.375 | 10.92%108.55 | -12.77%26.88 | 17.96%40 | 46.63%25.095 |
Dividend per share | 0 | 9.09%60 | 0.00%30 | 0 | 20.00%30 | 0 | 10.00%55 | 20.00%30 | 0 | 0.00%25 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |